(Q41689704)

7 October 2017

title

The Potential of SERMs for Reducing the Risk of Coronary Heart Disease (English)

1 reference

7 October 2017

author

Elizabeth Barrett-Connor

series ordinal

1

object named as

Barrett-Connor E

1 reference

7 October 2017

Cox DA

2

1 reference

7 October 2017

Anderson PW

series ordinal

3

1 reference

7 October 2017

publication date

1 October 1999

1 reference

Trends in Endocrinology and Metabolism

7 October 2017

published in

1 reference

7 October 2017

volume

10

1 reference

7 October 2017

issue

8

1 reference

7 October 2017

page(s)

320-325

1 reference

Coronary heart disease: an older woman's major health risk

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Hormone replacement therapy, heart disease, and other considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Compliance with hormone replacement therapy: Are women receiving the full impact of hormone replacement therapy preventive health benefits?

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

The effect of postmenopausal estrogen therapy on bone density in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Reduced mortality associated with long-term postmenopausal estrogen therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Droloxifene (3-hydroxytamoxifen) has membrane antioxidant ability: potential relevance to its mechanism of therapeutic action in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Antioxidant properties of the triphenylethylene antiestrogen drug toremifene

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Inhibition of LDL oxidation by a new estradiol receptor modulator compound LY-139478, comparative effect with other steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Effect of tamoxifen on measurements of hemostasis in healthy women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Homocysteine and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

A randomized controlled study of the effects of 17beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Tamoxifen reduces plasma homocysteine levels in healthy women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Coronary heart disease mortality and adjuvant tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Comparison between the Effects of Tamoxifen and Toremifene on the Uterus in Postmenopausal Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Design of the Women’s Health Initiative Clinical Trial and Observational Study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2899%2900182-4

7 January 2021

10.1016/S1043-2760(99)00182-4

Identifiers

DOI

1 reference

7 October 2017

1 reference